Free Trial
NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Verrica Pharmaceuticals logo
$0.77 -0.03 (-4.29%)
As of 12:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

Key Stats

Today's Range
$0.72
$0.79
50-Day Range
$0.41
$0.87
52-Week Range
$0.38
$8.98
Volume
346,646 shs
Average Volume
630,168 shs
Market Capitalization
$71.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Verrica Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

VRCA MarketRank™: 

Verrica Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 110th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verrica Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Verrica Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.46) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verrica Pharmaceuticals is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verrica Pharmaceuticals is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Verrica Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.43% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently decreased by 99.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Verrica Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Verrica Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.43% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently decreased by 99.41%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Verrica Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    54.00% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verrica Pharmaceuticals' insider trading history.
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Stock News Headlines

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com
This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Headlines

VRCA Stock Analysis - Frequently Asked Questions

Verrica Pharmaceuticals' stock was trading at $0.70 on January 1st, 2025. Since then, VRCA shares have increased by 4.0% and is now trading at $0.7280.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The firm earned $3.44 million during the quarter, compared to the consensus estimate of $2.53 million.
Read the conference call transcript
.

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Top institutional shareholders of Verrica Pharmaceuticals include Sovran Advisors LLC (0.81%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Ted White, Christopher G Hayes and Joe Bonaccorso.
View institutional ownership trends
.

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Marathon Oil (MRO), Centrus Energy (LEU) and Clean Energy Fuels (CLNE).

Company Calendar

Last Earnings
5/13/2025
Today
7/14/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VRCA
CIK
1660334
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$2.00
Potential Upside/Downside
+959.6%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.58 million
Net Margins
N/A
Pretax Margin
-919.21%
Return on Equity
N/A
Return on Assets
-145.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.34
Quick Ratio
1.26

Sales & Book Value

Annual Sales
$7.57 million
Price / Sales
9.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.11) per share
Price / Book
-6.86

Miscellaneous

Outstanding Shares
92,490,000
Free Float
42,546,000
Market Cap
$69.83 million
Optionable
Optionable
Beta
1.76
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:VRCA) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners